Time from drug approval to reimbursement longer in U.S. than some european countries

Time from approval to reimbursement of recent medication varies between nations and is shortest in Switzerland and Germany, each of which embrace well being know-how evaluation choices that aren’t utilized in the US, in accordance with a examine revealed on-line Sept. 3 within the Annals of Inner Drugs.

Camille E.G. Glaus, J.D., from the College of Zurich, and colleagues examined time from approval to reimbursement of recent medication in the US and European nations. New medication accredited in the US, the European Union, England, and Switzerland between Jan. 1, 2011, and Dec. 31, 2022, had been recognized, and reimbursement standing and dates had been extracted as of Dec. 31, 2023.

The examine included 290 medication accredited by all regulatory our bodies. The researchers discovered that the median time from approval to reimbursement was 5.8, 7.4, 9.2, 12.9, and 17.7 months in Switzerland, Germany, the US, France, and England, respectively. France had the very best reimbursement price one month after approval (25.9 %), adopted by Switzerland and England (9.7 and 0.7 %, respectively); at one month, the US and Germany had no medication reimbursed. Germany, the US, and Switzerland had the very best reimbursement charges of 74.3, 70.7, and 62.8 %, respectively, at one 12 months after approval; in England and France, the charges had been 37.1 and 49.0 %, respectively.

“Our findings recommend that incorporation of a well being know-how evaluation system and drug negotiation course of in the US wouldn’t essentially end in longer time till reimbursement,” the authors write.

Copyright © 2024 HealthDay. All rights reserved.